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Phorbol Myristate Acetate and Catechol as
Skin Cocarcinogens in SENCAR Mice
by Benjamin L. Van Duuren,* Susan Melchionne,* and
Irving Seidmant
The enhancement of the carcinogenicity of benzo(a)pyrene (B[a]P) and 3-propiolactone (BPL) by the
mouse skin cocarcinogens phorbol myristate acetate (PMA) and catechol were examined in female SEN-
CARmice, 30pergroup. Thecarcinogen andcocarcinogen wereappliedsimultaneously, threetimesweekly
for490-560days. B(a)PandBPLwereusedatconstantdosesof5and50jig, respectively, inallexperiments.
PMA was used at three doses, 2.5, 1.0, and 0.5 p.g per application, and catechol was used at one dose, 2
mg per application. Control groups included animals that received carcinogen only, cocarcinogen only,
acetone only, and no treatment. The carcinogenicity of B(a)P and BPL were enhanced by the cocarcin-
ogens, particularly in terms oftumor multiplicity. For both carcinogens, the most marked cocarcinogenic
effects were observed at the lowest dose of PMA used (0.5 ,ug per application). This observation applied
for days to first tumor, animals with tumors, tumor multiplicity, and incidence ofmalignant skin tumors.
Catechol applied alone did not induce any tumors; with PMA alone there were significant incidences of
benign and malignanttumors, e.g., at adose ofonly 0.5 ,ug perapplication, 15 of30 animals had 28tumors,
5 of which were squamous carcinomas. In two-stage carcinogenesis experiments with 7,12-dimethyl-
benz(a)anthracene (DMBA) as initiator and PMA as promoter, SENCAR mice showed a greater suscep-
tibility to tumor induction when compared to ICR/Ha mice used in earlier work. This susceptibility was
most notable in terms of rate of tumor appearance and tumor multiplicity.
Table 1. Protocols for two-stage carcinogenesis and
cocarcinogenesis.
The two-stage model for chemical carcinogenesis was
first described in the classic work of Berenblum (1,2),
who used mouse skin as the route of exposure. At the
same time, Berenblum showed that remarkable en-
hancement of the carcinogenic activity of benzo(a)-
pyrene [B(a)P] occurs whencrotonoiloritsconcentrate,
croton resin, and B(a)P are applied simultaneously and
repeatedly to mouse skin. The latter type of experi-
mental protocol was referred to by Berenblum as co-
carcinogenesis (1). Since that time, the mouse skin test
system has been used in many laboratories for studies
on two-stage carcinogenesis and, to a lesser extent, co-
carcinogenesis, and these endeavors have been re-
viewed (3,4). The two protocols as used by Berenblum
are summarized in Table 1.
One result ofthe early work was the development of
mouse lines that would be particularly sensitive to tu-
mor induction in two-stage carcinogenesis. The devel-
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Protocol
Two-stage Single application of initiator (DMBA,
carcinogenesis B(a)P, or BPL) followed by repeated
applications ofpromoter (PMA), i.e.,
sequential application of chemicals.
Cocarcinogenesis Repeated and simultaneous application of
carcinogen (B(a)P or BPL; low dose)
and cocarcinogen (PMA or catechol).
opment of sensitive mice was first accomplished in the
pioneering work of Boutwell (5), who explored the de-
velopmentofskintumor-susceptible (STS)micebycare-
ful inbreeding experiments usingtwo-stage carcinogen-
esis for selection of STS mice. The necessary
requirements of inbreeding and the small sizes of col-
onies used for the development of STS mice resulted in
the decline ofreproductive performance in these mice.
Thispoorbreedingperformancewasalleviatedbycross-
breedingmale STSmice with female Charles RiverCD-
1 mice. The details and history ofthe susceptible mice
thusdeveloped wererecentlydescribed (6). Thesemice,
originally maintained at the Oak Ridge National Lab-
oratory, have since than been named SENCAR mice.
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In the course of work on carcinogens, tumor pro-
moters, and cocarcinogens in tobacco smoke conden-
sate, it became necessary to examine some major com-
ponents of tobacco smoke for their tumor promoting
and/or cocarcinogenic properties. In human exposure to
cigarette smoke, there is simultaneous and repeated
intake of aromatic hydrocarbon carcinogens and many
other chemicals, some ofwhich were considered poten-
tial cocarcinogens. Many ofthe tobacco phenols, which
were suspected astumorpromoters based onthefinding
that phenol itselfis a weak tumor promoter (7), proved
to be inactive as tumor promoters using the two-stage
protocol (8). This proved to be the case for such com-
pounds as catechol, pyrene, fluoranthene, undecane,
and several others in a series of structurally unrelated
chemicals that were neither active as tumor promoters
in two-stage carcinogenesis nor carcinogens (8,9).
For continued studies on environmentally important
factors, particularly chlorinated humic acids, which oc-
cur in drinking water, it became relevant to explore the
use of SENCAR mice because of their reported in-
creased susceptibility to skin tumor induction (6).
In the chemical and biological work that resulted in
the isolation and structure elucidation of the phorbol
esters from croton oil, random-bred ICR/Ha mice were
used (10). These mice were also used in our subsequent
work on the promoter phorbol myristate acetate [PMA,
also referred to as (12-O-tetradecanoylphorbol-13-ace-
tate TPA)], including dose-response studies, the effect
of aging in two-stage carcinogenesis studies, and other
studies (4). The same mouse strain was also used in our
earlier studies on mouse skin cocarcinogens (9). Hence,
it became relevant to compare our earlier results using
ICR/Ha mice with results ofsimilar studies using SEN-
CAR mice.
When the work described in the present report was
undertaken in early 1980, reports indicated that SEN-
CAR mice are more susceptible to mouse skin tumor
induction than CD-1 mice (6) and BALB/c mice (11) in
two-stage carcinogenesis using several endpoints of
bioassays. In subsequentwork, DBA/2 mice were found
to be as sensitive as SENCAR mice, also in two-stage
carcinogenesis studies using PMA as a promoter (12).
The sensitivity of various mouse strains, including
SENCAR mice, to complete carcinogenesis and to the
initiation-promotion protocol has been rank ordered
(13).
The work described in this report deals with the use
of SENCAR mice in skin tumor induction mainly using
cocarcinogenesis protocols with B(a)P and ,B-propiolac-
tone (BPL) as carcinogens togetherwith the mouse skin
cocarcinogens PMA and catechol. The findings obtained
with SENCAR mice, described here are compared with
the earlier studies using ICR/Ha mice (4,9,14).
Methods
Animals, Housing, and Treatment
Female SENCAR mice were obtained from Oak
Ridge National Laboratories (Oak Ridge, TN) at ap-
proximately 4 weeks of age and were put on test at
approximately 6 weeks of age. There were 30 animals
per group. All chronic experiments were preceded by
short-termevaluationslasting4to6weekstodetermine
acceptable doses for chronic exposure. The doses se-
lected for short-term evaluation were based on those
used earlier with the same chemicals in ICR/Ha mice
(9,15). Forthetwo-stage experiments, the testduration
was 550 days and forcocarcinogenesis, thetest duration
was 490 or 560 days. The dorsal skins of all mice were
shaved at the beginning of experiments and then as
needed during the tests. Animal housing and care was
the same as that used before (9).
All animals were weighed at bimonthly intervals, and
records were maintained. Animals were observed for
tumor appearance daily; tumors were scored and ob-
servations were charted once per month. All solutions
were applied to the dorsal skin in 0.1 mL acetone by
micropipette except for 7-12-dimethylbenz-
(a)anthracene (DMBA), whichwasadministered bysub-
cutaneous injection in the left flank in 0.05 mL trica-
prylin per injection. The appropriate vehicle and no-
treatment control groups were included; treatment
groups and doses ofchemicals used are presented under
Results. In two-stage carcinogenesis experiments, a
single dose of DMBA was followed two weeks later by
thrice-weekly application of PMA. In the cocarcinoge-
nesis experiments, the two agents (B[a]P or BPL and
cocarcinogens PMA or catechol) were applied simulta-
neously forthe duration ofthe test. Animals were killed
at the conclusion oftests or when in moribund condition
and necropsied. Skin lesions were excised, sectioned,
and submitted for histopathologic diagnosis. Lesions
were counted as papillomas when they reached a size
of 1 mm3 and persisted for more than 30 days. Lesions
that regressed by day 30 or earlier were not counted in
the total cumulative tumors.
Chemicals
DMBA (Eastman Organic Chemicals, Rochester,
NY) was purified by recrystallization from 95% ethyl
alcohol to constant melting point of 122.5-123°C; fresh
solutions were prepared immediately before use in
bioassays. B(a)P (Aldrich Chemical Company) was re-
crystallized from benzene:methanol (1:3) to constant
melting point of 174-176°C. B(a)P solutions were pre-
pared once per month from freshly recrystallized ma-
terial. BPL (Sigma Chemical Company, St. Louis, MO)
was tested as >99% pure by gas chromatography and
used as such. Solutions of BPL were prepared freshly
once per week. Catechol (Fisher Scientific Co., Fair-
lawn, NJ) was purified by recrystallization from tol-
uene, mp 100-103°C. Its purity was checked by thin-
layer chromatography on silica gel (chloroform:ethyl
acetate, 1:1, RF 0.68). All solutions were prepared in
anhydrous acetone, and all pure chemicals and their
solutions were stored in amber-colored containers at
4°C. PMA used in the two-stage experiments was pre-
pared from croton oil, purified, and its purity checked
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Table 2. Two-stage carcinogenesis in SENCAR mice.'
Number Number of mice
of mice with malignant
Time to with tumors
first tumors/
tumor, total Squamous
Treatment and dose, ,ug days tumors carcinoma Sarcoma
Subcutaneous'
DMBA, 0.5, PMA 0.5 93 14/22 5 1
DMBA, 0.1, PMA, 0.5 120 16/32 10 0
DMBA, 0.5, acetone, 0.1
mL 540 1/1 1 0
DMBA, 0.1, acetone, 0.1
mL 0 0 0
Topicale
DMBA, 5, PMA, 0.5d 44 30/692 23 2
DMBA, 5, acetone, 0.1 mL 140 4/8 3 0
PMA, 0.5 170 13/22 4 1
Acetone, 0.1 mL 374 2/2 0 0
No treatmente 513 1/1 0 0
aInitiation by subcutaneous injection and by topical application of
DMBA; PMA by topical application; Test duration 550 days; Median
survival time > 550 days; 30 female mice per group.
'Injected subcutaneously in 0.05 mL tricaprylin in left flank once
only, followed 14 days later by three times weekly application ofPMA
in 0.1 mL acetone to dorsal skin.
'Single dorsalskinapplication ofDMBAin0.1 mL acetone, followed
14 days later by three times weekly application of PMA in 0.1 mL
acetone.
dTest duration: 400 days, median survival time: 311 days.
eSixty mice.
by thin-layer chromatography as described before (15).
PMA for the cocarcinogenesis experiments was ob-
tained from Lifesystems Co. (Newton, MA) and from
CCR Inc. (Eden Prairie, MN). Its purity was checked
by thin-layer chromatography as before (15). Solutions
for cocarcinogenesis bioassays were prepared by com-
bining proper concentrations of carcinogens and cocar-
cinogens once weekly so that the final concentrations in
the bioassaytest solutions werethose shownunder"Re-
sults." They were stored at 4°C in amber-colored con-
tainers. Solutions ofBPL combined with catechol were
stored at -20°C. To ensure that no reaction occurred
between BPL and catechol, bioassay solutions stored
under these conditions were checked for purity by gas
chromatography six days after preparation. Only the
peaks forthe pure components were noticed, and traces
of possible reaction products or other impurities were
not detectable.
Results
The sensitivity of SENCAR mice to two-stage car-
cinogenesis on skin using protocols that were used in
earlier work (4,14,15), was examined with DMBA as an
initiator at two doses (0.5 p,g and 0.1 ,ug) by the sub-
cutaneous route and at 5 ,ug by the topical route. PMA
was applied topically as apromoter at 0.5 pg/application
throughout. The low dose of PMA used, 0.5 pg per
application, was based on short-term evaluations of
SENCAR mice for skin irritancy. The results of this
experiment are shown in Table 2. Topical application of
DMBA followed by PMA gave the expected high inci-
dence of both benign and malignant tumors in the
DMBA-PMA group and also showed that DMBA and
PMA by themselves induced benign and malignant tu-
mors. The latter tumor incidences were markedly
higher than those observed earlier (4,14,15) in compa-
rable control groups with ICR/Ha mice.
DMBA administered subcutaneously at 1/10 and 1/50
ofthe dose used for skin initiation was still effective as
an initiator, but the tumor incidences were markedly
lower than those induced by skin application.
In the second series of experiments, the carcinogens
B(a)P or BPL were applied simultaneously and repeat-
edly with the mouse skin cocarcinogens PMA or ca-
techol. In these experiments, PMA was used at three
dose levels with a constant dose ofcarcinogen. Catechol
was used at one dose only. The results of these exper-
iments together with the results from appropriate con-
trol groups are shown in Table 3. Using B(a)P or BPL
as carcinogens, higher incidences of tumors were in-
duced with decreasing doses of PMA, from 2.5 to 0.5
,ug/application. Days to first tumors ranged from 49 to
85 days. The rates oftumorappearancereflected clearly
the inverse relationship between dose ofPMA and total
numbers oftumors as shown in Figures 1 and 2. In the
control group, B(a)P or BPL alone resulted in late ap-
pearance offirst tumors and lower incidences oftumors
after500 days on test than were seenwith simultaneous
application of PMA or catechol.
Discussion
In the evaluation ofthe relative susceptibility oftwo
ormore strains ofmice to skintumorinduction bychem-
icals, it is necessary to consider: (1) treatment regimen,
which can be a single chemical applied once only or
repeatedly (carcinogenesis), single treatment with an
initiator followed by repeated application ofa promoter
(two-stage carcinogenesis) or repeated treatment with
two chemicals applied simultaneously (cocarcinogene-
sis); (2) dose-response information; (3) class ofchemical
used, e.g., direct-acting or indirect-acting carcinogen,
type of promoter, or type of cocarcinogen; (4) duration
of treatment and subsequent observation; (5) animal
survival; (6) incidence of spontaneous tumors; and (7)
experimental observations that include: time to first tu-
mor, rate of tumor appearance, tumor multiplicity, tu-
morregression, and incidence ofmalignant tumors. Be-
cause ofthedifferences ingoalsofvariousinvestigators,
itisrarelypossible to obtain allthe desired information.
In the present work, the main purpose was to ex-
amine the susceptibility of SENCAR mice to tumor in-
duction in two-stage and cocarcinogenesis experiments
and to compare these findings with the same chemicals
used in our earlier work in the same experiments with
ICR/Ha mice. Only one two-stage carcinogenesis ex-
periment comparable to an earlier experiment (15) was
carried out in this work, the results ofwhich are shown
in Table 2. In both experiments, the dose regimen was
one application of DMBA, 5 jig, followed by PMA, 0.5
jig, thrice weekly for the duration ofthe tests. In ICR/
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Table 3. Cocarcinogenesis in SENCAR mice, 30 female mice per group.
Mice with malignant
tumors
Carcinogen + cocarcinogen and Median survival Time to first Mice with tumors/ Squamous
dose, p.g/applicationa Test duration, days time, days tumor, days total tumors carcinoma Sarcoma
Treatment groups
BP, 5 + PMA, 2.5b 560 372 50 27/334 21 1
l3P, 5 + PMA, 1.0 490 344 49 27/423 16 0
BP, 5 + PMA, 0.5 490 322 49 29/473 22 0
BP, 5 + Catechol, 2000b 560 310 179 30/192 25 0
BPL, 50 + PMA, 2.5b 560 447 69 16/36 10 1
BPL, 50 + PMA, 1.0 490 437 85 24/99 11 2
BPL, 50 + PMA, 0.5 490 404 57 28/124 19 0
BPL, 50 + Catechol, 2000b 560 >560 153 14/43 9 0
Control groups
BP, 5b 560 555 295 24/79 19 0
BPL, 50b 560 >560 293 2/4 1 0
PMA, 2.5b 560 515 277 10/12 4 0
PMA, 1.0 490 >490 141 15/24 8 0
PMA, 0.5 490 >490 85 15/28 5 0
Catechol, 2000b 560 >560 0 0 0
Acetone, 0.1 mL 500 >500 0 0 0
No Rx (65 mice) 520 >520 0 0 0
No Rx (60 mice) 570 >570 0 0 0
aCarcinogens: B(a)P and BPL; cocarcinogens: PMA and catechol applied to the dorsal skin simultaneously in 0.1 mL acetone three times
weekly for the duration of the test except where noted. For preparation of solutions, see "Methods."
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FIGURE 1. Rate of tumor appearance in skin cocarcinogenesis with
30 female SENCAR mice per group: B(a)P at 5.0 ,ug, PMA at
doses indicated. Applied simultaneously three times weekly.
Ha mice, 13 of20 animals had tumors after 365 days on
test, of which 3 had squamous carcinoma of the skin
(15). In SENCAR mice, all 30 animals had tumors, of
which 23 had squamous carcinomas and 2 had sarcomas.
The test duration was 365 days for ICR/Ha and 400
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FIGURE 2. Rate of tumor appearance in skin cocarcinogenesis with
30 female SENCAR mice per group: BPL at 50 jig, PMA at doses
indicated. Applied simultaneously three times weekly.
rable. There waslittle difference in daystofirsttumors,
which was 36 days for ICR/Ha mice and 44 days for
SENCAR mice. The most marked difference between
these mice was in tumor multiplicity, which averaged
2.7 per mouse for ICR/Ha mice and 23.6 for SENCAR
mice. In addition, the rate of tumor appearance was
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FIGURE 3. Rate of tumor appearance in two-stage carcinogenesis
with ICR/Ha and SENCAR mice, 20 females per group; 30 mg
BPL in 0.1 mL acetone once only, followed 3 days later by 5 jig
PMA in 0.1 mL acetone, 3 times weekly for 320 days.
much more rapid in SENCAR mice compared to ICR/
Ha mice, which is similar to what has been observed in
comparing SENCAR mice to other mouse strains (13).
The differences in tumor response between the two
strains depend on the dose of PMA used as promoter.
SENCAR mice are more sensitive to the irritant effect
of PMA than ICR/Ha mice. The optimal dose of PMA,
in terms of mice with tumors, tumor multiplicity, and
rate of tumor appearance, for SENCAR mice was 0.5
,ug per application (Table 2), whereas for ICR/Ha mice,
it was 25 ,ug (15). This comparison is based on a dose
of5 ,ug ofDMBA as initiator, a 14-day interval between
initiation and promotion, and thrice weekly application
ofPMA. It is not possible to extrapolate from this type
ofexperiment to other tumor initiators or promoters or
to mouse skin assays for complete carcinogens.
In another comparative two-stage carcinogenesis ex-
periment, BPL was used as the initiator, 30 mg, once
only in 0.1 mL acetone administered topically, followed
by PMA, 5 p,g per application, three times weekly for
320 days using a 3-day interval between initiation and
promotion(14). There were20female ICR/Haand SEN-
CAR mice per group. The rate oftumor appearance in
thisexperiment is showninFigure3. Unlike manyother
comparative studies that showed SENCAR mice to be
the more sensitive strain (13), ICR/Ha mice had more
rapid tumor appearance and final tumor yield. Days to
first tumor were close to 35 days for both groups. The
final tumor yields were 16 SENCAR mice with 55 tu-
mors (three carcinomas) and 18 ICR/Ha mice with 100
tumors (two carcinomas, one sarcoma).
The two differences between this experiment and the
one shown in Table 2 are the use of an indirect-acting
carcinogen (DMBA) in one case and a direct-acting car-
cinogen (BPL) in the other; and the use ofa higher dose
(5 jig) of PMA with BPL initiation compared to 0.5 ,ug
with DMBA initiation. It is likely that the high dose of
PMA resulted in decreased tumor yields in SENCAR
mice, as was observed in the cocarcinogenesis experi-
ments summarized in Table 3.
It has been observed in studies with PMA as pro-
moter in two-stage carcinogenesis experiments that
control groups receiving PMA alone develop a low in-
cidence of benign and malignant skin tumors (16). In
the present study using only SENCAR mice, the in-
duction ofbenign and malignant skin tumors with PMA
alone at three dose levels, shown in Table 3, was con-
siderably higher than that observed with PMA in ICR/
Ha mice (15). The lowest dose used, 0.5 ,ug PMA thrice
weekly, induced 28 tumors in 15 animals, 5 ofwhich had
carcinomas (Table 3). Similar findings were made when
the effect on SENCAR mice of PMA alone was com-
pared with the effect of PMA on other mouse strains,
CD-1 mice (6) and BALB/cmice (11), bothofwhich were
found to have lower tumor incidences than SENCAR
mice.
Theimportance ofdose-response studies is illustrated
in Figures 1 and 2, in which the results ofB(a)P or BPL
applied simultaneously with PMA (cocarcinogenesis) at
three dose levels are compared. In both cases, the high-
est rate of tumor appearance and highest tumor yields
were obtained at the lowest dose ofPMA used, 0.5 jig.
These results are probably due to increased skin inflam-
mationand hyperplasiaasthe dose ofPMAisincreased.
Duringthe course ofthe tests listed in Table 3, the skin-
damagingeffectsof2.5 jigofPMAappliedthriceweekly
became apparent. These effects were remedied by de-
creasing the frequency of application to twice weekly,
as noted in Table 3.
In the present work, studies on mouse skin cocarcin-
ogenesis were extended by examining the phenomenon
in SENCAR mice, by including in the present study
the direct-acting carcinogen BPL, and by including the
use of several doses of PMA as a cocarcinogen. The
results of the last set of experiments emphasized the
importance of using several doses of PMA in these co-
carcinogenesis experiments, aswas done inearlierstud-
ies on dose-response in two-stage carcinogenesis with
PMA as promoter (15). The potency of PMA as a skin
irritant necessitates careful consideration ofthis factor
in comparing different mouse strains in skin carcino-
genesis studies using the two protocols given in Table
1.
In addition to PMA, the cocarcinogen catechol was
used in the present work. The high dose of catechol
used in the study was arrived at on the basis of early
short-term evaluations of its skin irritancy (9). Since it
did not show any notable skin irritancy at 2 mg per
application, this dose was selected for use in cocarcin-
ogenesis experiments. No dose-response experiments
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Table 4. Conclusions: skin tumorigenesis in female ICR/Ha and
SENCAR mice.
Ranking Response
SENCAR > ICR/Ha Tumor multiplicity
Earlier peak response
Both 1 and 2 occur with polycyclic
aromatic hydrocarbons and PMA
SENCAR = ICR/Ha Minimum latent period
Pattern of morphologic development of
skin tumors by two-stage and
cocarcinogenesis protocols
Incidence of squamous carcinoma of the
skin in lifetime tests
ICR/Ha > SENCAR Tumor induction in two-stage
carcinogenesis after BPL initiation and
promotion by PMA
were carried out with this chemical, which is remark-
ably simple inchemical structure, yetbiologically active
ascocarcinogen. Catecholiscompletelydevoid oftumor-
promoting or carcinogenic activity in mouse skin using
both ICR/Ha (9) and SENCAR mice (present study).
Further work with this compound is indicated, both in
terms ofbiological activity, particularly dose response,
and mode of action.
From the work described in this report and findings
reported earlier in mouse skin cocarcinogenesis exper-
iments from the same laboratory with ICR/Ha mice
(9,14), limited comparative conclusions, listed in Table
4, were made. These conclusions apply only to the ex-
periments performed in our laboratory, within the dose
ranges used, for the duration oftreatment, and for the
chemicals used. Extrapolation to otherexperiments and
experimental conditions as enumerated atthebeginning
of this Discussion was not attempted.
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